Smoking is one of the strongest environmental factors linked to ulcerative colitis, but the relationship runs in the opposite direction from what most people expect. Across decades of research, current smoking is consistently associated with a lower risk of developing ulcerative colitis and milder disease when it does appear. A large meta-analysis of case-control studies found that smokers had roughly half the odds of developing UC compared to nonsmokers.1Scientific Reports. Relationship between smoking status and ulcerative colitis: a meta-analysis based on a case–control study This paradox has puzzled gastroenterologists for over 40 years and has fueled serious research into whether components of cigarette smoke could be harnessed as treatments without the obvious harms of tobacco.
How Strong Is the Epidemiological Evidence?
The association between smoking and reduced UC risk is one of the most replicated findings in inflammatory bowel disease research. An early case-control study at the Mayo Clinic found that current smokers were far less likely to have UC, with an odds ratio of 0.13 compared with people who had never smoked.2Mayo Clinic Proceedings. Cigarette Smoking and Ulcerative Colitis: A Case-Control Study More recent pooled analyses confirm the direction, though the magnitude varies across studies. A 2025 meta-analysis reported a combined odds ratio of 0.48 for smokers versus nonsmokers, and an even more dramatic ratio of 0.26 when comparing current smokers to ex-smokers.3Scientific Reports. Relationship between smoking status and ulcerative colitis: a meta-analysis based on a case–control study That last comparison matters because ex-smokers are actually at the highest risk of all three groups, a pattern that gets at one of the most clinically important features of this association.
This is not a small or tentative finding. Reviews spanning multiple countries and populations consistently show that current smoking is inversely associated with UC onset and disease progression.4PubMed Central. Ulcerative colitis in smokers, non-smokers and ex-smokers The effect is strong enough that some gastroenterologists factor smoking status into their diagnostic workup: a patient who smokes heavily and presents with bloody diarrhea raises somewhat less suspicion for UC than a former smoker with the same symptoms, all else being equal. Active smoking has also been linked to reduced rates of colectomy, lower risk of primary sclerosing cholangitis (a serious liver complication), and less extensive colitis, with higher daily cigarette consumption correlating with less need for therapy.5PubMed. Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis
What Happens When You Quit Smoking?
For people with UC who smoke and then stop, the consequences can be striking. A study tracking UC patients before and after they quit found that cessation was followed by an increase in the rate of years with active disease, years requiring hospitalization, and years needing heavy-duty medications like oral steroids and azathioprine.6PubMed. Impact of cessation of smoking on the course of ulcerative colitis Many gastroenterologists have seen this play out: a patient quits smoking for their lungs and heart, then within months has their worst UC flare in years.
The risk of developing UC after quitting may persist for a remarkably long time. Research suggests that the elevated risk associated with ex-smoking status can persist for 20 years or more after cessation.7Inflammatory Bowel Diseases. Differential Impact of Smoking on Methylome and Transcriptome in Crohn’s Disease and Ulcerative Colitis This long tail hints that whatever smoking does to protect against UC involves durable biological changes, not just the transient presence of smoke chemicals in the body. Clinicians managing UC patients who want to quit smoking often plan for potential flares during the transition, sometimes adjusting maintenance therapy preemptively.
Why Would Smoking Protect Against UC?
Researchers have explored several mechanisms, and the honest answer is that no single explanation fully accounts for the effect. Nicotine gets the most attention, but the picture is more complicated than “nicotine helps colitis.”
The leading hypothesis centers on the alpha-7 nicotinic acetylcholine receptor, a protein on immune cells that acts as part of the body’s built-in braking system for inflammation. When nicotine binds to this receptor, it triggers a chain of events that dials down the production of inflammatory signaling molecules and reduces the infiltration of aggressive immune cells into the colon wall. In animal models of colitis, drugs that activate this receptor reduced weight loss, bleeding, colon shortening, and tissue damage while suppressing multiple inflammatory signals.8PubMed Central. Protective effect of α7 nicotinic acetylcholine receptor activation on experimental colitis and its mechanism Mice lacking this receptor developed more severe colitis, while activating it promoted a cellular cleanup process that reduced inflammation through pathways involving energy-sensing machinery in cells.9PubMed. Alpha7 Nicotinic Acetylcholine Receptor Alleviates Inflammatory Bowel Disease Through Induction of AMPK-mTOR-p70S6K-Mediated Autophagy
But nicotine may not be the only actor. Cigarette smoke contains thousands of compounds, and researchers have pointed out that nicotine is broken down into various metabolites in the body, some of which could be the real protective agents.10Wiley Online Library (Inflammatory Bowel Diseases). Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis Beyond nicotine, carbon monoxide from cigarette smoke has shown anti-inflammatory properties in colitis models. In mice with a form of colitis that resembles UC, carbon monoxide suppressed inflammation through a pathway involving an enzyme called heme oxygenase-1.11PubMed Central. An Anti-Inflammatory Role for Carbon Monoxide and Heme Oxygenase-1 in Chronic Th2-Mediated Murine Colitis Active smokers carry measurably higher levels of carbon monoxide in their blood, so this is not just a theoretical exposure.
Other proposed mechanisms include changes in gut blood flow, alterations in the mucus layer that lines the colon, and shifts in how the immune system balances its various arms of defense.12Inflammatory Bowel Diseases. Inflammatory Bowel Disease and Smoking: A Review of Epidemiology, Pathophysiology, and Therapeutic Implications The reality is likely that multiple components of cigarette smoke act on multiple pathways simultaneously, making it difficult to isolate one “active ingredient.”
How Smoking Reshapes the Gut Microbiome
Smoking changes the community of bacteria living in your gut, and some of these changes may contribute to the protective effect in UC. Smokers tend to have shifts in the balance of major bacterial groups, with increases in some and decreases in others, along with an overall reduction in microbial diversity.13PubMed. Smoking and the intestinal microbiome These changes are significant because the gut microbiome plays a central role in how the immune system behaves in the colon.
A particularly interesting finding comes from recent work showing that people with UC who smoke have higher levels of short-chain fatty acids in their stool compared to those who quit, along with increased presence of certain oral bacteria in their colonic tissue. One of these displaced oral species, when introduced alone into germ-free mice, triggered the production of specific immune cells in the colon and reduced inflammation in a mouse model of UC while worsening a Crohn’s disease model.14Gut. Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota This finding is striking because it helps explain why smoking has opposite effects in the two main forms of inflammatory bowel disease: protective in UC but harmful in Crohn’s. The microbiome may be one of the channels through which smoking exerts these divergent effects.
Has Nicotine Been Tried as a UC Treatment?
Given the epidemiological data, researchers have spent decades testing whether nicotine itself could be used to treat UC without the rest of the cigarette. The results have been mixed and, on balance, disappointing enough that nicotine never became a mainstream therapy.
The best-known trial, published in the New England Journal of Medicine, randomized 72 patients with active UC to either transdermal nicotine patches or placebo. About half the patients on nicotine achieved complete remission, compared with about a quarter on placebo. The nicotine group also had lower stool frequency, less abdominal pain, and less urgency. But the side effects were substantial: nausea, lightheadedness, headache, and sleep disturbance were common, and significantly more patients on nicotine experienced adverse events.15PubMed. Transdermal nicotine for active ulcerative colitis
A Cochrane review that pooled data from two trials found a statistically significant benefit for transdermal nicotine over placebo in inducing remission. Roughly 27% of patients on nicotine achieved remission versus about 13% on placebo. However, patients on nicotine were also nearly six times more likely to drop out due to adverse events and about three and a half times more likely to report side effects overall. The review found no advantage for nicotine patches over standard medical therapy.16PubMed. Transdermal nicotine for induction of remission in ulcerative colitis In other words, nicotine patches worked better than a sugar pill but not better than the drugs already being prescribed for UC, and they came with significant tolerability problems.
A review of the broader literature on transdermal nicotine concluded that patches alone were no better than placebo but, when combined with conventional therapy like mesalazine or steroids, the combination offered superior results to either treatment individually.17PubMed Central. Transdermal Nicotine as a Treatment Option for Ulcerative Colitis: A Review This “add-on” benefit is interesting but has not been sufficient to establish nicotine as a standard adjunctive treatment, partly because the optimal dose and tolerability remain unresolved.
Researchers also tried delivering nicotine directly to the colon via enemas, hoping to reduce systemic side effects. A small pilot study showed encouraging results, with most patients improving their symptom scores when nicotine enemas were added to conventional treatment.18PubMed. Nicotine enemas for active ulcerative colitis–a pilot study Another pilot in patients with left-sided UC unresponsive to first-line therapy found that about 71% showed clinical and visual improvement after four weeks.19PubMed. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study But a larger randomized trial of 6-milligram nicotine enemas found no benefit over placebo, with remission rates of 27% in the nicotine group and 33% in the placebo group.20Gastroenterology. A Randomized Trial of Nicotine Enemas for Active Ulcerative Colitis
The current consensus is that nicotine therapy has limited application. It may be considered only in selected cases of acute UC that have not responded to conventional treatments, not as a first-line or routine option.21PubMed. Ulcerative colitis, smoking and nicotine therapy
Do E-Cigarettes Have the Same Effect?
This is a natural question for anyone aware of the smoking-UC link, and the answer so far is that e-cigarettes do not appear to reproduce the protective association. A case-control study looking at e-cigarette use in IBD patients found that current vaping was not associated with better or worse UC outcomes.22PubMed. E-cigarette Use and Disease Outcomes in Inflammatory Bowel Diseases: A Case-Control Study This is only one study, and the evidence base is thin, but it aligns with the broader suspicion that the protective effect of smoking is not purely about nicotine delivery.
There is also reason to think e-cigarettes could harm the gut in their own ways. Animal research on e-cigarette vapor exposure found significant damage to the colonic lining, including loss of the protective epithelial layer, heavy immune cell infiltration, a decrease in mucus-producing cells, and increased markers of oxidative stress and inflammation. These changes reversed after four weeks of cessation.23PubMed Central. Impact of e-cigarettes on colonic mucosa and the role of recovery: involvement of oxidative and inflammatory pathway The picture that emerges is that switching from cigarettes to e-cigarettes would not be a way to preserve whatever gut-protective benefit smoking might offer, and vaping may introduce its own colonic risks.
Gender Differences in the Smoking Effect
The protective effect of smoking on UC is not equally distributed between men and women, and this is an underappreciated nuance. A large population-based study found that the preventive effect of current smoking on UC development was observed only in men.24PubMed. Dose-response relationship between cigarette smoking and risk of ulcerative colitis: a nationwide population-based study Another study found that current smoking delayed the average age at which UC appeared by about nine years in men but had no effect on age of onset in women. Smoking also significantly reduced the need for immunosuppressant drugs in men with UC but not in women.25Gastroenterology. Gender differences in the response of colitis to smoking
Research from a large Korean cohort added further detail. In male ex-smokers, the risk of developing UC was elevated regardless of what age they started smoking, with those who began before age 20 seeing roughly twice the risk of nonsmokers. In women, most ex-smokers and current smokers did not differ significantly from nonsmokers in UC risk, with only a narrow exception for female ex-smokers who started smoking very young.26PubMed Central. Smoking Experience before Adulthood Is Associated with an Increased Risk of Developing Ulcerative Colitis in Adult Ex-Smokers Why the effect tracks so strongly with sex is not well understood, but hormonal differences in nicotine metabolism and immune regulation are plausible explanations.
Childhood Secondhand Smoke Exposure
Whether growing up around smokers influences your adult risk of UC is genuinely unsettled science. An early case-control study reported that people whose parents smoked had about half the odds of developing UC, suggesting passive childhood exposure might confer some of the same protection as active smoking.27PubMed. Childhood exposure to environmental tobacco smoke and the risk of ulcerative colitis But a meta-analysis that combined results from multiple studies found no overall association between childhood passive smoke exposure and UC, with a pooled odds ratio of 1.01.28PubMed Central. Passive Smoking and Inflammatory Bowel Disease: A Meta-analysis
Confusingly, at least one study found the opposite: that passive smoking exposure at birth was associated with an increased risk of developing IBD in children, with a stronger effect for Crohn’s disease than UC.29PubMed. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children The discrepancy likely reflects differences in study design, timing of exposure measurement, and the difficulty of separating passive smoke exposure from other household environmental factors. For now, secondhand smoke exposure in childhood cannot be confidently called either protective or harmful for UC risk.
Epigenetic Changes and Long-Lasting Biological Marks
One reason the smoking effect persists so long after quitting may involve epigenetic changes, modifications to how genes are read without changing the DNA sequence itself. Research comparing the molecular fingerprints of smokers and nonsmokers with IBD found that smoking left distinct marks on gene activity in UC. Certain inflammatory pathways were turned down in UC patients who smoked, and a specific epigenetic change on a gene called MGAT3 was linked to more severe disease course only in UC, not in Crohn’s disease.30PubMed Central. Differential Impact of Smoking on Methylome and Transcriptome in Crohn’s Disease and Ulcerative Colitis These molecular modifications can persist long after the original exposure ends, which helps explain why ex-smokers remain at elevated UC risk for decades. It also opens the door to understanding which specific genetic switches are involved, potentially pointing toward therapeutic targets that could mimic the beneficial effects without any smoke or nicotine at all.
Appendectomy and Other Interacting Factors
Smoking is not the only environmental factor that shows a curious protective association with UC. Having had an appendectomy, particularly for appendicitis in youth, has been independently linked to lower UC risk. A study that tracked UC patients over time found that both prior appendectomy and current smoking independently reduced the likelihood of needing a colectomy, with appendectomy cutting the hazard by about 60% and smoking by about 40%.31PubMed Central. Effects of appendicectomy on the course of ulcerative colitis The fact that these two protective factors work independently suggests they operate through different mechanisms, though both likely involve shifts in how the immune system surveys the gut.
Smoking status also tracks with long-term outcomes in ways that matter for clinical decision-making. Smokers with UC are less likely to require oral steroids and have lower rates of colectomy over a decade of follow-up.32PubMed. Effect of smoking on the long-term course of ulcerative colitis None of this means a gastroenterologist would ever advise a patient to smoke. The cardiovascular, pulmonary, and cancer risks of tobacco vastly outweigh any benefit to the colon. But recognizing smoking status as a disease modifier helps clinicians anticipate flares, plan medication adjustments around cessation attempts, and understand why one patient’s disease behaves differently from another’s.